Archives: Agenda

• How is the industry approaching diversity and what should the primary focus be?
• Increasing accessibility to trials whilst simultaneously maintaining an appropriate level of patient safety
• Assessing the link between restrictive eligibility criteria and rates of serious adverse events to make informed decisions on expanding exclusion conditions
• Alternative solutions to improve patient numbers amidst pressures to hit recruitment milestones
• How have increased pressures of patient recruitment lead to the questioning of traditional enrollment methods?

Chair: Cathy Scharf, Patient Advocate, Patient Advocates of the East Bay

• In-home trial delivery makes participation easier, more convenient and more accessible
• Increasing trial access to more patients by empowering and supporting a variety of community research sites
• How trial design can deliver increased recruitment and retention in a cost-effective way

• Trends observed during the JP Morgan Healthcare conference
• The impact of the new administration on clinical trials

• How independent adjudication improves endpoint accuracy and consistency in trials.
• Ways adjudication improves data accuracy and regulatory compliance.
• Strategies to reduce risk and streamline trial timelines.
• How to reduce variability and disputes in clinical endpoint assessments.

• Evolution of CRO FSP models
• Balancing growth and quality in a hybrid model
• The future of scaling and offshore integration

• Prioritizing your organizational structure and goals
• Key considerations for developing a bespoke outsourcing framework
• Building resilient outsourcing strategies that align with future clinical development needs